Ann: US Patent Office to allow key patent for Progenza, page-4

One of RGS' strengths over the years has been to deliver on promises. They may be one or two months late on the Japanese licensing agreement, but credit is due when it comes to their strategy, especially IP strategy.
The way they have got around the issues of their first patent (opposition from VetStem and Pittsburg University) is remarkable.
They have put themselves in a unique situation with advanced research and great patenting strategy. They really own the space of MSC secretions and therapeutic application. Commercial licensing from Progenza will follow through as they come in Japan, US and Europe too.
And then the same will happen with Sygenus...
Well done!